Weight Loss Wars: Eli Lilly's Zepbound and Mounjaro Challenge Novo Nordisk's Dominance

Novo Nordisk is the current leader in the weight-loss drug market with blockbuster treatments like Wegovy and Ozempic. However, Eli Lilly is mounting a challenge with its fast-rising competitors Mounjaro and Zepbound. Eli Lilly has announced positive results for its Phase 3b SURMOUNT-5 trial, showing that Zepbound outperforms Novo Nordisk's Wegovy in weight loss. Lilly's Mounjaro and Zepbound have generated $5.2 billion and $3.4 billion in global sales, respectively, in the second quarter, leading to a 38% increase in total revenue and a 61% growth in adjusted earnings. Lilly is scaling its production capacity to meet rising demand and has raised its 2025 full-year revenue guidance to $60 billion to $62 billion.

The weight-loss drug market has been one of the fastest-growing sectors in recent years, with Novo Nordisk (NVO) and Eli Lilly (LLY) emerging as the primary competitors. Novo Nordisk, a Danish pharmaceutical giant, has been the market leader with its blockbuster drugs, Wegovy and Ozempic. However, Eli Lilly has been making significant strides with its competitors, Mounjaro and Zepbound, challenging Novo Nordisk's dominance.

In May 2025, Eli Lilly announced the results of its Phase 3b SURMOUNT-5 trial, which showed that Zepbound (tirzepatide) outperformed Novo Nordisk's Wegovy (semaglutide) in helping adults with obesity or overweight achieve significant weight loss. Over 72 weeks, participants on Zepbound lost an average of 20.2% of their body weight compared to 13.7% on Wegovy, a 47% greater relative reduction Weight Loss Wars: Is Novo Nordisk’s Dominance Safe Against Eli Lilly?^[1].

Eli Lilly's Mounjaro and Zepbound generated $5.2 billion and $3.4 billion in global sales, respectively, in the second quarter of 2025, leading to a 38% increase in total revenue and a 61% growth in adjusted earnings. Lilly has been rapidly scaling its production capacity for incretin therapies, projecting to produce at least 1.8 times the number of sellable doses in 2025 compared to 2024. This expansion ensures the company can fulfill rising global demand for treatments such as Mounjaro and Zepbound Weight Loss Wars: Is Novo Nordisk’s Dominance Safe Against Eli Lilly?^[1].

Novo Nordisk, valued at $248 billion, has also seen significant growth in its weight-loss drug sales. However, the company has faced challenges due to lawsuits alleging inadequate notification about serious adverse effects of its treatments. Despite this, Novo Nordisk reported earnings per share of 12.49 DKK in the first half of 2025, an increase of 23% year-over-year, and total sales grew 16% over the same period last year Weight Loss Wars: Is Novo Nordisk’s Dominance Safe Against Eli Lilly?^[1].

In the second half of 2025, Novo Nordisk forecasts decreased growth for its GLP-1 medicines, particularly for Wegovy in the US obesity market and for Ozempic in the US GLP-1 diabetes market. This led to a reduction in full-year guidance, estimating 8% to 14% CER sales growth in 2025 Weight Loss Wars: Is Novo Nordisk’s Dominance Safe Against Eli Lilly?^[1].

On Wall Street, Eli Lilly has earned an overall "Strong Buy" rating, with 18 out of 27 analysts rating it a "Strong Buy" and the average analyst price target of $898.58 suggesting a 24% increase from current levels. In contrast, Novo Nordisk stock is a "Moderate Buy," with nine analysts rating it a "Strong Buy" and nine a "Hold" Weight Loss Wars: Is Novo Nordisk’s Dominance Safe Against Eli Lilly?^[1].

Eli Lilly's recent earnings report shows that the company is well-positioned to sustain near- and long-term growth. The stock has surged 58.3% compared to the S&P 500 Health Care Index's 12.4% gain, making Lilly a Wall Street powerhouse in the growing $100 billion anti-obesity industry Eli Lilly’s Zepbound Rockets Sales, Sends Shares to Historic $978 Peak^[2].

In conclusion, while Novo Nordisk has been the market leader in weight-loss drugs, Eli Lilly's Zepbound and Mounjaro have shown significant promise. Lilly's strong earnings, rapid production scaling, and robust R&D pipeline make it a better investment for growth-oriented portfolios.